Tamoxifen tablet survey a mixed bag for Dara


Dara Biosciences (DARA), which provides a liquid version of the Tamoxifen treatment for breast cancer, finds that the adherence of patients to the tablet form "is less than optimal."

In a survey, 14% of respondents said they miss two or more Tamoxifen doses a month, while 8% had swallowing difficulties.

Seven percent said a liquid version of Tamoxifen would boost their compliance and 22% said they'd be willing to try it.

Shares are +3.7% premarket. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs